In the third quarter, HeartWare International (HTWR) had better than expected sales of its cardiac pumps and as a result, its share price moved up substantially.
The jump in sales was driven by the widespread acceptance of HeartWare's HVADs (ventricular assist device), particularly in foreign markets, in line with predictions made at the time the device was launched in the U.S. a year ago.
Some predict now that HeartWare is destined to take over the leadership of the heart pump industry in the next few years from current leader, Thoratec (THOR).
The company is still losing money, although the loss has narrowed to $11.4 million from $25.0 million a year ago.
In December HeartWare bought...
Only subscribers can access this article, which is part of the PRO research library covering 3,559 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: